Golden State Equity Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Golden State Equity Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$41.7K	Buy	+326	New	+$40.7K	﹤0.01%	925
2024 Q4	–	Sell	-25	Closed	-$2.47K	–	891
2024 Q3	$2.47K	Buy	+25	New	+$2.46K	﹤0.01%	684
2023 Q4	$521K	Buy	5,835 +59	+1%	+$4.38K	0.13%	182
2023 Q3	$422K	Buy	5,776 +736	+15%	+$58.8K	0.12%	188
2023 Q2	$419K	Buy	5,040 +1,156	+30%	+$96.7K	0.12%	206
2023 Q1	$296K	Buy	+3,884	New	+$322K	0.16%	150

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Golden State Equity Partners's XBI Position: Q1 2026 in Review

Golden State Equity Partners opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q1 2026: 326 shares worth $41.7K. The stake represents ﹤0.01% of the portfolio and ranks #925 among its holdings. This is a return to the name: Golden State Equity Partners previously reported a position in XBI as recently as Q3 2024.

Golden State Equity Partners first reported a position in XBI in Q1 2023 and has held it in 6 quarters since. The position peaked at $521K in Q4 2023. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Golden State Equity Partners held 326 shares of State Street SPDR S&P Biotech ETF worth $41.7K as of Q1 2026.
State Street SPDR S&P Biotech ETF was a new Golden State Equity Partners position in Q1 2026.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Golden State Equity Partners's portfolio in Q1 2026, its #925 holding.
Golden State Equity Partners first reported a position in State Street SPDR S&P Biotech ETF in Q1 2023 and has held it in 6 quarters since.
Golden State Equity Partners's State Street SPDR S&P Biotech ETF position peaked at $521K in Q4 2023.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Golden State Equity Partners's 13F filing for Q1 2026, filed 28 Apr 2026.